The efficacy and tolerability of pharmacologic treatment options for Lennox‐Gastaut syndrome. (September 2014)

• Record Type: Journal Article
• Authors: Montouris, Georgia D.; Wheless, James W.; Glauser, Tracy A.
• Is Part Of: Epilepsia. Volume 55:(2014)Supplement 4
• Page Start: 10
• Page End: 20
• Publication Date: 2014-09
• Subjects: Tonic seizure -- Atonic seizure -- Atypical absence seizure -- Myoclonic seizure -- Tonic–clonic seizure; Epilepsy -- Periodicals; 616.853
• DOI: 10.1111/epi.12732
• Languages: English
• ISSNs: 0013-9580

Abstract

Summary: Lennox‐Gastaut syndrome (LGS) is a severe epileptic encephalopathy that appears in childhood. LGS is characterized by a slow spike‐wave pattern on electroencephalogram (EEG), cognitive impairment, and multiple seizure types. This mixture of seizure types, along with the need to use more than one type of medication, makes LGS one of the most complicated epilepsies to treat successfully. Recent developments in approved therapies for the treatment of LGS offer physicians more options, but also make developing a treatment strategy that minimizes adverse events more challenging. There are currently 5 treatment options for LGS: felbamate, lamotrigine, topiramate, rufinamide, and clobazam, and several others that are used off‐label, each of which has benefits and limitations. There are several factors that must be considered when determining which medication to use when treating patients with LGS, including efficacy, which is assessed by seizure frequency, tolerability, and the anticipated duration of treatment. In this article, data supporting current treatment options are discussed, and important considerations about the treatment of LGS are reviewed.